Prulifloxacin is a fluoroquinolone antibacterial prodrug utilized to treat various bacterial infections by inhibiting bacterial DNA replication, after being metabolized in the body into its active form,… Read more
![Chemical structure of Ethyl 6,7-difluoro-1-methyl-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F113046-72-3-Ethyl-67-difluoro-1-methyl-4-oxo-4H-13thiazeto32-aquinoline-3-carboxylate.png&w=3840&q=75)
![Chemical structure of Ethyl 6-fluoro-1-methyl-4-oxo-7-(1-piprazinyl)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F113028-17-4-Ethyl-6-fluoro-1-methyl-4-oxo-7-1-piprazinyl-4H-13thiazeto32-aquinoline-3-carboxylate.png&w=3840&q=75)








Prulifloxacin is a fluoroquinolone antibacterial prodrug utilized to treat various bacterial infections by inhibiting bacterial DNA replication, after being metabolized in the body into its active form, ulifloxacin. This category features a comprehensive collection of high-quality reference standards, including the parent drug, its specific synthetic and degradation-related impurities, and stable isotope labelled compounds. These materials are essential for pharmaceutical laboratories engaged in rigorous analytical testing, impurity profiling, and method validation. By utilizing these characterized standards, researchers can ensure accurate identification and quantification during quality control processes and regulatory compliance documentation. The availability of isotopically labelled analogues, such as deuterium-labelled forms, further supports precise mass spectrometry-based assays, allowing for reliable pharmacokinetic studies and bioanalysis of this therapeutic agent throughout the drug development lifecycle.